`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`RANBAXY LABORATORIES LTD and RANBAXY, INC.,
`
`Petitioners
`
`'ADAMAS PHARMACEUTICALS, INC.,
`
`Patent Owner
`
`Inter Pam: Review No.: 201500410
`
`U.S. Patent No. 8,362,085
`
`PETITIONERS’ UPDATED POWER OF ATTORNEY
`
`
`
`
`
`PETITIONERS’ UPDATED POWER OF ATTORNEY
`
`Petitioners, Ranbaxy Laboratories Ltd. and Ranbaxy, Inc., hereby appoint
`
`practitioners associated with Kenyon & Kenyon LLP, Customer Number 26,646,
`
`including the following lead and backup counsel:
`
`Lead Counsel
`
`Back-up Counsel
`
`Karen C. Shen
`John W. Bateman
`(Reg. No. 60,412)
`(Reg. No. 41,602)
`KENYON 8: KENYON LLP KENYON & KENYON LLP
`
`Fax: 212.425.5288
`
`1500 K Street, NW
`Washington, DC 20005
`jbateman@kenyon. corn
`Tel: 202.220.4216
`
`Fax: 202.220.4201
`
`One Broadway
`New York, NY 10004—1007
`kshen@kenyon.com I
`Tel: 212.908.6206
`
`as its attorneys to prosecute the inter partes review proceeding relating to U.S.
`
`' Patent 8,262,085 and to transact all business in the United States Patent and
`
`Trademark Office associated with an inter partes'review of U.S. Patent No.
`
`8,262,085.
`
`The undersigned is empowered to act on behalf of Petitioner.
`
`RANBAXY LABORATORIES LTD and RANBAXY, 'INC.
`
`['7 ‘7 P'fi
`Name: Kathryn Jones
`Title:- Director, Intellectual Property
`Date: February 17, 2015
`
`
`
`
`
`